# OnCo record paper-abida-triton2-rucaparib-brca-jco-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-abida-triton2-rucaparib-brca-jco-2020" ;
  schema:name "TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration"@en ;
  schema:alternateName "TRITON2"@en, "Abida 2020 rucaparib"@en ;
  schema:description "The trial that got rucaparib approved for prostate cancer. In 115 men with a BRCA fault whose cancer had already been through hormone drugs and chemotherapy, around half had their tumours shrink or their PSA halve."@en ;
  schema:url <https://onco.cc/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/jco.20.01035>, <https://pubmed.ncbi.nlm.nih.gov/32795228/>, <https://clinicaltrials.gov/study/NCT02952534>, <https://doi.org/10.1200/JCO.20.01035>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0295d202-1cfe-7659-e063-6294a90a476e> ;
  onco:tag "prostate-evidence" ;
  schema:sameAs <https://doi.org/10.1200/jco.20.01035> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Abida W, Patnaik A, Campbell D, et al." ;
  onco:related <https://onco.cc/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/>, <https://onco.cc/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/>, <https://onco.cc/key-papers/paper-profound-nejm-2020/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/rucaparib/> ;
  onco:companies <https://onco.cc/companies/clovis-oncology/> ;
  onco:pathways <https://onco.cc/pathways/homologous-recombination-repair/>, <https://onco.cc/pathways/base-excision-repair-parp/>, <https://onco.cc/pathways/synthetic-lethality-map/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/synthetic-lethality/>, <https://onco.cc/terms/psa/>, <https://onco.cc/terms/genome-wide-loss-of-heterozygosity/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/psa50/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-regulatory-fragmentation/> ;
  onco:journals <https://onco.cc/journals/jco/> .